Preda Agnesa, Preda Silviu-Daniel, Mota Maria, Iliescu Dominic Gabriel, Zorila Lucian George, Comanescu Alexandru Cristian, Mitrea Adina, Clenciu Diana, Mota Eugen, Vladu Ionela Mihaela
Department of Obstetrics and Gynecology, Clinical County Emergency Hospital Craiova, 200642 Craiova, Romania.
Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Biomedicines. 2024 Oct 3;12(10):2252. doi: 10.3390/biomedicines12102252.
Dyslipidemia in pregnancy presents unique clinical challenges due to its effects on maternal and fetal health. This systematic review hypothesizes that molecular alterations in lipid metabolism during pregnancy contribute to adverse pregnancy outcomes and seeks to identify the clinical implications of these changes. The rationale behind this review stems from the increased risk of complications such as preeclampsia, intrauterine growth restriction, and acute pancreatitis associated with dyslipidemia in pregnancy. The primary objective is to examine the interplay between lipid metabolism and pregnancy outcomes.
To achieve this, a systematic review following PRISMA guidelines was conducted, with a comprehensive search of the PubMed database covering articles from January 2014 to June 2024. Inclusion criteria focused on studies assessing molecular alterations and clinical outcomes of dyslipidemia in pregnancy, while case reports and relevant clinical trials were analyzed to evaluate both maternal and fetal outcomes. A total of 12 studies were included in the final analysis.
This study provided evidence of the need for early detection and management strategies to reduce risks. The outcomes revealed significant associations between dyslipidemia and adverse maternal outcomes such as preeclampsia, gestational diabetes, and pancreatitis, as well as fetal outcomes like preterm birth and fetal distress.
Early lipid monitoring and intervention are crucial in mitigating these risks and suggests that a multidisciplinary approach is necessary to improve maternal and fetal health in pregnancies complicated by dyslipidemia.
妊娠期间的血脂异常因其对母婴健康的影响而带来独特的临床挑战。本系统评价假设妊娠期间脂质代谢的分子改变会导致不良妊娠结局,并试图确定这些变化的临床意义。该评价的基本原理源于妊娠期间血脂异常相关的并发症风险增加,如子痫前期、胎儿生长受限和急性胰腺炎。主要目的是研究脂质代谢与妊娠结局之间的相互作用。
为实现这一目标,按照PRISMA指南进行了系统评价,全面检索了PubMed数据库中2014年1月至2024年6月的文章。纳入标准侧重于评估妊娠期间血脂异常的分子改变和临床结局的研究,同时分析病例报告和相关临床试验以评估母婴结局。最终分析共纳入12项研究。
本研究提供了证据,表明需要早期检测和管理策略以降低风险。结果显示血脂异常与子痫前期、妊娠期糖尿病和胰腺炎等不良母体结局以及早产和胎儿窘迫等胎儿结局之间存在显著关联。
早期脂质监测和干预对于减轻这些风险至关重要,并表明多学科方法对于改善合并血脂异常的妊娠中的母婴健康是必要的。